News

Video

ASCRS 2024: Enrollment begins in Canada for cell therapy trial, targeting corneal endothelial disease

At the 2024 ASCRS Greg Kunst, CEO of Aurion Biotech relayed the latest news from Aurion and the company's work in cell therapies for corneal endothelial disease.

At the 2024 ASCRS meeting in Boston, Massachusetts, we spoke with Greg Kunst, CEO of Aurion Biotech. He relayed the latest news from Aurion and the company's work in cell therapies for corneal endothelial disease.

Video Transcript:

Editor's note: The following transcript has been lightly edited for clarity.

Greg Kunst:

Hello, I'm Greg Kunst, CEO of Aurion Biotech. We're here at the 2024 American Society of Cataract and Refractive Surgeons, and Aurion Biotech this week is talking about our novel cell therapy targeting corneal endothelial disease. We'll be presenting two papers, one on the use of our cell therapy, not only in corneal endothelial disease but in conjunction with cataract surgery. We'll also be showing a paper where, from our trial in El Salvador, where we compare the the drug, our drug as a combination drug with cells and with Rho-kinase, versus cells alone.

Additionally, we announced just this past week that we have enrolled our first patients in Canada. We're nearing full enrollment in our Phase 1/2. We expect sometime next year to be able to present that data. Stay tuned for when that that data becomes available. Thank you very much. Have a great rest of your day.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
Patricia Buehler, MD, MPH, founder and CEO of Osheru, talks about the Ziplyft device for noninvasive blepharoplasty at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Bonnie An Henderson, MD, on leveraging artificial intelligence in cataract refractive surgery
(Image credit: Ophthalmology Times) ASCRS 2025: Gregory Moloney, FRANZO, FRCSC, on rotational stability
Sheng Lim, MD, FRCOphth, discusses the CONCEPT study, which compared standalone cataract surgery to cataract surgery with ECP, at the 2025 ASCRS Annual Meeting.
(Image credit: Ophthalmology Times) ASCRS 2025: Steven J. Dell, MD, reports 24-month outcomes for shape-changing IOL
© 2025 MJH Life Sciences

All rights reserved.